← All Senti Biosciences, INC filings

Senti Biosciences, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
SNTI
Senti Biosciences, INC
DEFA14A: Senti Biosciences Files Definitive Proxy Statement
Senti Biosciences has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.
NASDAQ
SNTI
Senti Biosciences, INC
DEF: Senti Biosciences Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Senti Biosciences will hold its 2025 Annual Meeting of Stockholders virtually on June 25, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.
NASDAQ
SNTI
Senti Biosciences, INC
DEF: Senti Biosciences Seeks Stockholder Approval for Share Issuance and Equity Plan Changes
Senti Biosciences is holding a special meeting to seek stockholder approval for a share issuance related to a recent private placement and to amend its equity incentive plan.
NASDAQ
SNTI
Senti Biosciences, INC
DEFA14A: Senti Biosciences Files Definitive Proxy Statement
Senti Biosciences has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.
NASDAQ
SNTI
Senti Biosciences, INC
DEF 14A: Senti Biosciences Seeks Stockholder Approval for Officer Exculpation, Reverse Stock Split at July 10, 2024 Annual Meeting
Senti Biosciences is holding its 2024 Annual Meeting of Stockholders virtually on July 10, 2024, to vote on key proposals including officer exculpation, a reverse stock split, and ratification of KPMG LLP as the independent auditor.